title: Adjudin disrupts spermatogenesis by targeting drug transporters: Lesson from the breast cancer resistance protein (BCRP).
abstract: For non-hormonal male contraceptives that exert their effects in the testis locally instead of via the hypothalamic-pituitary-testicular axis, such as adjudin that disrupts germ cell adhesion, a major hurdle in their development is to improve their bioavailability so that they can be efficiently delivered to the seminiferous epithelium by transporting across the blood-testis barrier (BTB). If this can be done, it would widen the gap between their efficacy and general toxicity. However, Sertoli cells that constitute the BTB, peritubular myoid cells in the tunica propria, germ cells at different stages of their development, as well as endothelial cells that constitute the microvessels in the interstitium are all equipped with multiple drug transporters, most notably efflux drug transporters, such as P-glycoprotein, multidrug resistance-related protein 1 (MRP1) and breast cancer resistance protein (BCRP) that can actively prevent drugs (e.g., adjudin) from entering the seminiferous epithelium to exert their effects. Recent studies have shown that BCRP is highly expressed by endothelial cells of the microvessels in the interstitium in the testis and also peritubular myoid cells in tunica propria even though it is absent from Sertoli cells at the site of the BTB. Furthermore, BCRP is also expressed spatiotemporally by Sertoli cells and step 19 spermatids in the rat testis and stage-specifically, limiting to stage VII‒VIII of the epithelial cycle, and restricted to the apical ectoplasmic specialization [apical ES, a testis-specific F-actin-rich adherens junction (AJ)]. Interestingly, adjudin was recently shown to be capable of downregulating BCRP expression at the apical ES. In this Opinion article, we critically discuss the latest findings on BCRP; in particular, we provide some findings utilizing molecular modeling to define the interacting domains of BCRP with adjudin. Based on this information, it is hoped that the next generation of adjudin analogs to be synthesized can improve their efficacy in downregulating BCRP and perhaps other drug efflux transporters in the testis to improve their efficacy to traverse the BTB by modifying their interacting domains.
authors.affiliation: The Mary M. Wohlford Laboratory for Male Contraceptive Research; Center for Biomedical Research, Population Council; New York, NY USA ; Department of Anatomy, Histology and Embryology; School of Basic Medicine; Peking Union Medical College; Beijing, China.
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Qian
authors.forename: Yan-Ho
authors.initials: YH
authors.lastname: Cheng
authors.forename: Pranitha
authors.initials: P
authors.lastname: Jenardhanan
authors.forename: Dolores D
authors.initials: DD
authors.lastname: Mruk
authors.forename: Premendu P
authors.initials: PP
authors.lastname: Mathur
authors.forename: Weiliang
authors.initials: W
authors.lastname: Xia
authors.forename: Bruno
authors.initials: B
authors.lastname: Silvestrini
authors.forename: C Yan
authors.initials: CY
authors.lastname: Cheng
keywords: Bcrp; adjudin; ectoplasmic specialization; male contraception; spermatogenesis; testis